Download full-text PDF

Source
http://dx.doi.org/10.1159/000332380DOI Listing

Publication Analysis

Top Keywords

papillary thyroid
8
thyroid carcinoma
8
familial adenomatous
4
adenomatous polyposis-associated
4
polyposis-associated papillary
4
carcinoma indolent
4
indolent course
4
course belongs
4
belongs cribriform-morular
4
cribriform-morular variant
4

Similar Publications

Influence of Body Mass Index on the Clinicopathological Features of Papillary Thyroid Carcinoma in a Chinese Population.

Metab Syndr Relat Disord

January 2025

NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China.

Previous studies suggested a relationship between obesity and a high risk of thyroid cancer. However, the association between high body mass index (BMI) and the aggressiveness of papillary thyroid carcinoma (PTC) is controversial. In this study, we aimed to investigate the impact of excess BMI on histopathologic aggressiveness of PTC in a Chinese population.

View Article and Find Full Text PDF

Purpose: Long noncoding RNAs (lncRNAs) play crucial regulatory roles in the tumorigenesis and progression of various cancers. However, the functional roles of lncRNAs in papillary thyroid cancer (PTC) remain unclear. In this study, we investigated the functional role of the lncRNA FAM111A-DT in PTC progression and the underlying mechanisms.

View Article and Find Full Text PDF

Purpose: This study systematically evaluated the diagnostic performance of dual-energy computed tomography (DECT) quantitative parameters in detecting cervical lymph node metastasis in patients with papillary thyroid cancer (PTC).

Method: We searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and Wanfang Data databases for relevant original studies from database inception to March 2024. The quality of the included studies was evaluated using the QUADAS-2 tool.

View Article and Find Full Text PDF

Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), albiglutide (Tanzeum), dulaglutide (Trulicity), lixisenatide (Lyxumia, Adlyxin), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound), are widely used for the treatment of type 2 diabetes mellitus (T2DM) and obesity. While these agents are well known for their metabolic benefits, there is growing interest in their potential effects on cancer biology. However, the role of GLP-1R agonists in cancer remains complex and not fully understood, particularly across different tumor types.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!